Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;23(2):152.
doi: 10.3892/etm.2021.11075. Epub 2021 Dec 17.

Cardiovascular comorbidities in psoriasis (Review)

Daciana Elena Branisteanu  1 , Alin Codrut Nicolescu  2 , Daniel Constantin Branisteanu  3 , Catalina Ioana Branisteanu  4 , Andreea Corina Dragoi  5 , Camelia Margareta Bogdanici  3 , Mihaela Paula Toader  6 , Andreea Lorena Tucaliuc  5 , Andreea Dimitriu  7 , Doru Daogaru  8 , Ruxandra Angela Pirvulescu  9   10 , Elena Andrese Porumb  11
Affiliations
Review

Cardiovascular comorbidities in psoriasis (Review)

Daciana Elena Branisteanu et al. Exp Ther Med. 2022 Feb.

Abstract

Long considered a skin-limited condition, psoriasis is currently defined as a chronic, immune-mediated inflammatory disease, presenting, besides the skin changes, important systemic manifestations, the most common being: psoriatic arthritis, cardiovascular disease, metabolic syndrome, diabetes, inflammatory bowel disease and nonalcoholic steatohepatitis. It is a disease with a strong psycho-emotional and social impact, both through skin changes such as pruritic, scaly erythematous plaques, and through the association of comorbidities that influence morbidity and mortality. It has been shown that psoriasis is an independent cardiovascular risk factor, with patients developing ischemic heart disease/acute coronary syndrome, hypertension, peripheral arterial disease, or stroke. The chronic inflammatory status of psoriasis and the production of specific cytokines may be the etiopathogenic link to atherosclerosis and cardiovascular disease. Biological therapy may affect atherosclerosis, leading to the arrest of the evolution or even regressing the changes in the atheromatous plaque. The aim of this review was to re-evaluate the current knowledge regarding the cardiovascular comorbidities associated with psoriasis for optimal management of the patients.

Keywords: biologic agents; cardiovascular disease; pathogenesis; psoriasis comorbidities; screening; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that they have no competing interests.

References

    1. Kang S. Psoriasis. In: Fitzpatrick's Dermatology. 9th edition. Vol 1, McGraw-Hill Education, New York, NY, pp457-494, 2019.
    1. Porumb-Andrese E, Vâță D, Postolică R, Stătescu L, Stătescu C, Grăjdeanu AI, Pătrașcu AI, Popescu IA, Solovastru LG. Association between personality type, affective distress profile and quality of life in patients with psoriasis vs. patients with cardiovascular disease. Exp Ther Med. 2019;18:4967–4973. doi: 10.3892/etm.2019.7933. - DOI - PMC - PubMed
    1. Batani A, Branisteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G, Caruntu C. Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 2018;15:1241–1246. doi: 10.3892/etm.2017.5542. - DOI - PMC - PubMed
    1. Taranu T, Toader MP, Esanu I. The importance of dual dermatologic and psychiatric approach in psychocutaneous disorders. Rom J Oral Rehab. 2016;8:18–27.
    1. Van de Kerkhof PC, Nestlé FO. Psoriasis. In: Dermatology. Bolognia J, Schaffer J and Cerroni L (eds). 4th edition. Vol 1, Elsevier, Philadelphia, pp138-158, 2017.